Article Date

Many autologous cell therapy manufacturers are investigating next generation, allogeneic replacements for their existing therapies.

Significant capital is being invested globally to design and construct autologous cell therapy facilities. These first generation personalised cell therapies scale out to cater for high patient population. This results in space intensive facilities and is the reason the focus is now turning to next generation, allogeneic replacements.

PM Group's Principal Architect, Arantxa Lera and Advanced Therapies Process SME, Tom Bannon, will present on transitioning existing facilities from autologous to allogeneic operations. They will demonstrate how existing buildings can adapt to allogeneic operations.

This presentation will highlight the attributes of autologous and allogeneic cell therapy facilities, and outline the manufacturing challenges in transitioning between these. They will show the challenges existing facilities will face in transitioning to allogeneic, and will outline how new facilities can be designed to be adaptable and/or flexible to facilitate this development in a compliant manner that does not affect therapy quality.

Join Arantxa and Tom at the ISPE Singapore Affiliate’s Technical Tuesday

Date: 22nd February 2022

Time: 5.30-6.30pm SGT.

Register here.